阿托伐他汀对高血压病患者血浆sICAM-1水平和PAI-1活性的影响  

Effects of Atorvastatin on Plasma Level of sICAM-1 and PAI-1 Activity in Patients with Essential Hypertension

作　　者：陈然[1] 黄红光[1] 刘江陵[1] 程春[1] 黄玉艳[1] 

机构地区：[1]长沙市中心医院心内科,湖南长沙410000

出　　处：《医学临床研究》2011年第6期1083-1085,共3页Journal of Clinical Research

摘　　要：【目的】探讨高血压病（EH）患者血浆细胞间粘附分子-1（siCAM-1）水平和纤溶酶原激活物抑制剂-1（PAI-1）活性的变化及阿托伐他汀对其的影响。【方法】采用酶联免疫吸附法（ELlSA）、发色底物显色法分别对155例轻至中度高血压患者应用阿托伐他汀治疗前后和正常对照组者血浆siCAM-1水平和PAI-1活性进行检测。【结果】高血压患者血浆siCAM-1水平和PAI-1活性明显高于正常对照组（P〈0．01及P〈0．05），经阿托伐他汀治疗8周后其浓度明显下降（P〈0．01及P〈0．05）。【结论】高血压病患者血浆sI-cAM-1水平和PAI-1活性较正常人明显升高，阿托伐他汀在有效调脂的同时能降低高血压患者血siCAM-1浓度和PAI-1活性，减少高血压并发症的发生。[Objective]To explore the change of plasma level of soluble intercellular adhesion molecule-1 （sICAM-1） and plasminogen activator inhibitor-1 （PAI-1） activity and the effect of atorvastatin on them in patients with essential hypertension. [Methods]Enzyme linked immunosorbent assay（ELISA） and spectrophot metric assay were used to measure the plasma level of sICAM-1 and PAI-1 activity in 155 patients with mild to moderate essential hypertension before and after atorvastatin treatment and 8 normal controls. [Results] Plas- ma level of sICAM-1 and PAI-1 activity in hypertensive patients were significantly higher than those in normal controls（ P〈0.01 and P〈0.05）. Plasma level of sICAM-1 and PAI-1 activity in hypertensive patients significantly decreased after 8 weeks of atorvastatin treatment（ P〈0.01 and P d0.05）. [Conclusion]Compared with normal people, the plasma level of sICAM-1 and PAI-1 activity in hypertensive patients increase significantly. Atorvastatin can not only decrease blood lipids, but also decrease the level of sICAM-1 and PAI-1 activity, and reduce the incidence of the complications of hypertension.

关 键 词：高血压/药物疗法 降血脂药/药理学 胞间粘附分子1/血液 纤溶酶原激活物抑制物1/血液 

分 类 号：R544.1[医药卫生—心血管疾病]